EUCTR2004-003774-29-IT进行中（未招募）不适用
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with THERAKOS* UVADEX* for the Treatment of Patients with Newly Diagnosed Acute Graft-versus-Host Disease - Acute GvHD-1
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- THERAKOS
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent must be obtained prior to conducting any study procedure Patients must be >= 18 years old and weigh >= 40 kg (88 lb) Patients must have received an allogeneic hematopoietic BMT or PBSCT with myeloablative or reduced-intensity conditioning and have a new onset of acute GvHD, Grades II to III, which includes the skin and developed within 100 days following an allo-HPCT Patients must have received an allogeneic hematopoietic BMT or PBSCT from a related or unrelated donor that is matched at a minimum at the HLA-A, -B, and -DR loci (i.e., at least a 6 out of 6 match). HLA-A and -B match should be determined by serologic testing, and HLA-DR should be matched by molecular methods Patients must be receiving only a calcineurin inhibitor at study entry as part of their acute GvHD prophylactic regimen. Patients may have received additional immunosuppressants for acute GvHD prophylaxis prior to study entry Patients must have a Karnofsky performance >= 50 Patients must be able and willing to comply with all study procedures. Key inclusion and exclusion criteria (continued) Patients must receive, or must have received, the first corticosteroid dose of approximately 2.0 mg/kg/day but no more than 2.5 mg/kg/day (methylprednisolone equivalent) within 24 hours of the initial diagnosis of Grade II to III acute GvHD. (Up to 2.5 mg/kg/day is allowed for inadvertent dosing fluctuations for reasons other than lack of response.) Female patients must be one of the following: postmenopausal, surgically incapable of bearing children, practicing an acceptable method of birth control (acceptable methods include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. Male patients must also commit to using adequate contraceptive precautions (condoms). All patients (both males and females of childbearing potential) must commit to using adequate contraceptive precautions throughout their participation in the study and for at least 3 months following their last ECP treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have been diagnosed with chronic GvHD, including de novo chronic GvHD, prior to 100 days following an allo-HPCT Patients who have received donor lymphocyte infusions Patients with uncontrolled life-threatening infections Patients who have a white blood cell (WBC) count < 1.5 x 109/L (1,500/?L) Patients who have a platelet count < 20.0 x 109/L (20,000/?L), despite platelet transfusion Patients whose total bilirubin is >= 22 mg/dL Patients who have an International Normalized Ratio (INR) >= 2 Patients who are enrolled in any concomitant investigation for the treatment of acute GvHD Patients who are unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe chronic obstructive pulmonary disease, severe asthma, renal failure, hepatic encephalopathy, or hepatorenal syndrome Patients who have a known hypersensitivity or allergy to psoralen (methoxsalen) Patients who have a known hypersensitivity or allergy to both heparin and citrate products Patients who have co-existing melanoma, basal cell or squamous cell skin carcinoma, aphakia, photosensitive disease (e.g., porphyria, systemic lupus erythematosus, or albinism), white blood cell count > 25,000 cells/mm3, previous splenectomy, or coagulation disorders.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with Therakos Uvadex for the Treatment of Patients with Newly Diagnosed Acute Graft-Versus Host DiseaseGraft-versus-Host DiseaseEUCTR2004-003774-29-GBTherakos, Inc.240
进行中（未招募）
不适用
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with Therakos Uvadex for the Treatment of Patients with Newly Diagnosed Acute Graft-Versus Host DiseaseGraft-versus-Host DiseaseEUCTR2004-003774-29-ATTherakos, Inc.240
进行中（未招募）
1 期
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with Therakos Uvadex for the Treatment of Patients with Newly Diagnosed Acute Graft-Versus Host DiseaseGraft-versus-Host DiseaseEUCTR2004-003774-29-DETherakos, Inc.240
进行中（未招募）
不适用
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with Therakos Uvadex for the Treatment of Patients with Newly Diagnosed Acute Graft-Versus Host DiseaseGraft-versus-Host DiseaseEUCTR2004-003774-29-BETherakos, Inc.240
进行中（未招募）
不适用
A Controlled, Randomised, Parallel Group, Multicentre Study of the Efficacy and Safety of Herpes Simplex Virus-Thymidine Kinase Gene Therapy (CereproTM), with Subsequent Ganciclovir, for the Treatment of Patients with Operable High Grade Malignant Glioma - ASPECTOperable primary glioblastomaMedDRA version: 7.0Level: PTClassification code 10018338EUCTR2004-000464-28-CZArk Therapeutics Limited250